FOLH1 and prostate carcinoma: Research into newer diagnostics and treatments for PCa surged in 1993 when the Prostate Cancer Foundation (PCF) started funding projects aimed at a deeper understanding of a recently discovered transmembrane protein highly expressed in the prostate gland: PSMA.